Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bitopertin in adults with non-transfusion-dependent beta-thalassemia
2016-004799-23Phase 2Terminated
- Sponsor
- Roche
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bitopertin in beta thalassemia and Thalassaemia, sponsored by Roche. Primary endpoints: Incidence and severity of adverse events and serious adverse events, Incidence of treatment discontinuations due to adverse events and 8 more. Started May 2019; status: terminated.
02
Drugs
bitopertin
03
Conditions
beta thalassemiaThalassaemia
Beyond the preview
Go deeper on 2016-004799-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004799-23.